GlassScriptPhysician profile
Joachim Hertel
NPI 1538146303
$1,164.76
in general payments reported to CMS, 2019-2025
26 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $264 · 2021: $97.35 · 2022: $164 · 2023: $106 · 2024: $153 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.90 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $194.05 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $121.47 | 2019 | |
| Akebia Therapeutics INC | $95.48 | 2022-2024 | Vafseo |
| Rockwell Medical, INC. | $80.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $62.34 | 2021-2025 | |
| Baxter Healthcare | $55.75 | 2024 | |
| Daiichi Sankyo INC. | $54.37 | 2019-2025 | Injectafer |
| Calliditas Therapeutics US INC. | $53.86 | 2022-2024 | Tarpeyo |
| Amgen INC. | $48.67 | 2023-2024 | Tavneos |
| Horizon Therapeutics Plc | $46.23 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.51 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $33.62 | 2024-2025 | Lupkynis |
| Arbor Pharmaceuticals, INC. | $30.09 | 2019 | |
| Travere Therapeutics, INC. | $27.33 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.26 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.33 | 2021 | |
| Ardelyx, INC. | $22.16 | 2023 | Ibsrela |
| Mallinckrodt Enterprises LLC | $19.03 | 2019 | |
| Medtronic, INC. | $18.45 | 2022 | |
| Abbott Laboratories | $18.36 | 2022 | |
| Glaxosmithkline, LLC. | $17.41 | 2025 | Arexvy, Shingrix |
| Genzyme Corporation | $17.06 | 2021 | |
| Gilead Sciences, INC. | $16.99 | 2024 | |
| Scpharmaceuticals INC. | $16.94 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.37 | 2023 | Keveyis |
| Alexion Pharmaceuticals, INC. | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joachim Hertel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.